Vandetanib angiogenesis inhibitors

Description Results NMA

ORR 2.42 [1.42; 4.12]

OS 0.89 [0.73; 1.09]

PFS 0.83 [0.68; 1.01]

Vandetanib plus pemetrexed (n=-9)

vs.

pemetrexed (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

phase 3

vandetanib or placebo as maintenance (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

phase 2

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint: progression-free survival (PFS) rate at 3 months

FU duration:

phase II

vandetanib 300 mg/d (n=617)

vs.

placebo (n=307)

Sample size: 617/307

Primary endpoint: overall survival

FU duration:

once-daily vandetanib 300 mg (n=83)

vs.

gefitinib 250 mg (n=85)

double-blind

Sample size: 83/85

Primary endpoint:

FU duration:

phase ii

vandetanib 100 mg/d plus pemetrexed 500 mg/m(2) every 21 days (n=256)

vs.

placebo plus pemetrexed (n=278)

double-blind

Sample size: 256/278

Primary endpoint: Progression-free survival (PFS)

FU duration:

(n=-9)

vs.

(n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

phase ii

vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) (n=-9)

vs.

placebo plus docetaxel (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

phase II